Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients
Liver International,  Clinical Article

Lee SS et al. – The study confirmed the safety and tolerability profile of peginterferon alfa–2aribavirin and identified patient subgroups at higher risk of dose reductions and discontinuations, thus allowing optimum management of adverse events (AEs).

Methods
  • Patients were assigned at the investigator's discretion to 24- or 48-week treatment with peginterferon alfa-2a 180 μg/week and ribavirin 800 mg/day or 1000/1200 mg/day.
  • All AEs, defined as SAEs and non-SAEs of special interest, were recorded during treatment and for 12 weeks thereafter.
  • Non-SAEs of special interest included those leading to dose reduction/discontinuation, neutropenia, thrombocytopenia, anaemia, ALT elevations leading to dose modification and unknown/unexpected AEs.

Results
  • Of 1675 and 7178 patients assigned to 24 and 48 weeks of treatment, respectively, 87.6 and 68.3% completed therapy, whereas 6.4 and 10.3% prematurely stopped peginterferon alfa-2a treatment because of AEs.
  • Among patients assigned to 24 and 48 weeks, 37.4 and 46.9%, respectively, reported any AE (SAE or non-SAE of special interest); 4.2 and 6.6% reported SAEs and 35.2 and 44.0% reported non-SAEs of special interest.
  • Female gender, increasing age and cirrhosis were significantly associated with dose reductions of either drug.
  • Increasing age (and female gender in the case of ribavirin) was significantly associated with treatment discontinuation.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Infectious Disease

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Infectious Disease Articles

1 Duke team brings life-saving function to ketchup packets Duke University Health & Medicine News, July 3, 2014

2 Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: A systematic review and meta-analysis International Journal of Antimicrobial Agents, October 7, 2014    Evidence Based Medicine    Review Article

3 Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women Journal of Acquired Immune Deficiency Syndromes, October 24, 2014    Clinical Article

4 Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United States Neurology®, October 24, 2014    Evidence Based Medicine    Clinical Article

5 A systematic review: Can one prescribe carbapenems to patients with IgE-mediated allergy to penicillins or cephalosporins? Clinical Infectious Diseases, October 6, 2014    Review Article

6 Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis Clinical Gastroenterology and Hepatology , September 19, 2014    Clinical Article

7 Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: The SATURN-HIV Trial Clinical Infectious Diseases, August 15, 2014    Clinical Article

8 Antimicrobial lock solutions as a method to prevent central line-associated bloodstream infections: A meta-analysis of randomized controlled trials Clinical Infectious Diseases, October 20, 2014    Evidence Based Medicine    Clinical Article

9 Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: A systematic review and meta-analysis International Journal of Antimicrobial Agents, August 11, 2014    Evidence Based Medicine    Review Article

10 Antistaphylococcal penicillins versus cephalosporins for definitive treatment of methicillin-susceptible bacteraemia: A systematic review and meta-analysis International Journal of Antimicrobial Agents, September 30, 2014    Evidence Based Medicine    Review Article

11 Topical vancomycin in combination with perioperative antibiotics and tight glycemic control helps to eliminate sternal wound infections The Journal of Thoracic and Cardiovascular Surgery, July 17, 2014    Clinical Article

12 Did CDC's 2006 revised HIV testing recommendations make a difference? evaluation of HIV testing in the US household population, 2003–2010 Journal of Acquired Immune Deficiency Syndromes, October 16, 2014    Clinical Article

13 Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: A systematic review and meta-analysis International Journal of Infectious Diseases, September 22, 2014    Evidence Based Medicine    Review Article

14 Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: An update of data from a randomised, double-blind, phase 3 trial The Lancet Infectious Diseases, October 8, 2014    Clinical Article

15 California trees nailed as the source of mystery infections Duke University Health & Medicine News, August 26, 2014

16 A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection The Journal of Clinical Pharmacology, October 9, 2014    Evidence Based Medicine    Review Article

17 HPV and lung cancer risk: A meta-analysis Journal of Clinical Virology, October 22, 2014    Evidence Based Medicine

18 Effectiveness of a dental care intervention in the prevention of lower respiratory tract nosocomial infections among intensive care patients: A randomized clinical trial Infection Control and Hospital Epidemiology, October 24, 2014    Clinical Article

19 Antimicrobial lock solutions as a method to prevent central line-associated bloodstream infections: A meta-analysis of randomized controlled trials Clinical Infectious Diseases, August 27, 2014    Evidence Based Medicine    Clinical Article

20 Clinical management of staphylococcus aureus bacteremia: a review JAMA, October 1, 2014    Evidence Based Medicine    Review Article    Clinical Article

Indexed Journals in Infectious Disease: Journal of Infection, AIDS, American Journal of Infection Controlmore